Concord Biotech Ltd

Concord Biotech Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Concord Biotech Ltd

₹ 2,019 1.41%
22 Nov - close price
concordbiotech.com BSE: 543960 NSE: CONCORDBIO
About

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Key Points

Busines segments
A) APIs[1] Co manufactures API's through fermentation and semi-synthetic processes, across therapeutic areas of immunosuppressants, oncology, and anti-infectives
B) Formulations[2] which are used in therapeutic areas of immunosuppressants, nephrology and anti-infective drugs for critical care.

Website BSE NSE
  • Market Cap ₹ 21,125 Cr.
  • Current Price ₹ 2,019
  • High / Low ₹ 2,664 / 1,221
  • Stock P/E 64.4
  • Book Value ₹ 152
  • Dividend Yield 0.43 %
  • ROCE 28.1 %
  • ROE 21.1 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Stock is trading at 13.3 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE 500 BSE 400 MidSmallCap Index BSE Healthcare Nifty 500 BSE SmallCap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
181 159 241 273 195 262 241 319 216 310
116 121 131 146 123 147 135 187 135 176
Operating Profit 65 37 110 127 72 116 106 132 81 134
OPM % 36% 24% 46% 47% 37% 44% 44% 41% 38% 43%
14 6 9 12 13 8 11 11 12 10
Interest 1 1 1 1 1 1 0 0 0 0
Depreciation 14 13 14 14 13 13 14 14 13 13
Profit before tax 64 30 105 124 71 110 103 129 80 130
Tax % 23% 26% 26% 26% 23% 26% 25% 26% 25% 27%
49 22 77 91 54 81 78 95 60 96
EPS in Rs 51.79 2.10 7.40 8.75 5.21 7.74 7.41 9.08 5.70 9.15
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
512 616 713 853 1,017 1,086
308 289 443 504 585 633
Operating Profit 205 327 270 349 432 453
OPM % 40% 53% 38% 41% 42% 42%
32 14 23 37 37 44
Interest 1 1 6 10 3 1
Depreciation 21 28 50 54 54 54
Profit before tax 214 313 238 322 413 442
Tax % 21% 25% 26% 25% 25%
169 235 175 240 308 328
EPS in Rs 177.81 247.44 183.93 22.95 29.45 31.34
Dividend Payout % 22% 0% 3% 0% 30%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 18%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 9%
TTM: 8%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 61%
Return on Equity
10 Years: %
5 Years: %
3 Years: 19%
Last Year: 21%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 10 10 10 10 10 10
Reserves 761 990 1,094 1,280 1,516 1,580
52 86 62 32 10 3
118 97 147 192 164 171
Total Liabilities 941 1,183 1,313 1,514 1,701 1,764
240 546 573 593 575 558
CWIP 141 18 74 173 211 249
Investments 199 141 74 137 246 276
361 477 592 611 668 682
Total Assets 941 1,183 1,313 1,514 1,701 1,764

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
155 207 246 265
-114 -112 -158 -155
-43 -100 -85 -99
Net Cash Flow -1 -4 3 12

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 131 105 119 117 125
Inventory Days 312 503 434 430 331
Days Payable 201 152 185 190 150
Cash Conversion Cycle 242 456 368 357 306
Working Capital Days 160 180 177 163 169
ROCE % 32% 21% 26% 28%

Shareholding Pattern

Numbers in percentages

6 Recently
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
44.08% 44.08% 44.08% 44.08% 44.08%
7.30% 7.00% 6.49% 7.11% 8.10%
8.12% 8.40% 8.41% 10.35% 9.82%
40.50% 40.52% 41.03% 38.46% 38.02%
No. of Shareholders 1,00,92787,48683,29680,73784,298

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls